Intravenous thrombolysis prior to mechanical thrombectomy did not benefit patients with acute ischemic stroke due to a large vessel occlusion.
Warfarin protected against ischemic stroke, major bleeding, and all-cause mortality in patients who continued to take the drug after dementia diagnosis.
The triple-validated SeLECT score may help identify patients suited for antiepileptic drug trials.
Women with a history of migraine headache had a more than 2-fold increased risk of stroke over a 6-year follow-up period.
Recent research found benefits in outcome outweighed any increase in hemorrhagic complications in patients with large infarcts.
Another class of antacids, H2 receptor antagonists, had no impact on stroke risk.
Serious adverse events, especially those requiring hospitalization, may indicate an elevated risk of stroke.
The neuroprotective effect was evident after at least 6 months of use.
Although the study did not demonstrate efficacy of glyburide, differences were seen in the amount midline shift at 3-4 days.
Patients with acute ischemic stroke experienced less disability when treated with early endovascular thrombectomy.
Cerebral microbleeds increase the risk for symptomatic ICH after thrombolysis for acute ischemic stroke.
Being overweight may slightly lower chances for hemorrhagic stroke, the study found.
The Trevo devices are the first to be indicated for use in conjunction with IV tPA.
Studies have linked GCA with increased risk of VTE; however, results have been compromised by limited data sets.
Four blood biomarkers are associated with an increased risk of ischemic stroke.
In mice, the protein triggered the stem cells to become functioning neurons.
Associations with increased mortality were found for both low and high hemoglobin levels, suggesting a U-shaped relationship.
The findings are relevant for patients with insulin resistance but no history of diabetes.
Incidence of ischemic stroke does not appear to be influenced by exposure to tumor necrosis factor(TNF)-inhibitor use in patients with rheumatoid arthritis.
Still, regional variations exist, indicating that more personalized prevention programs may be needed.
Time, however, still plays a big role in stroke outcomes.
Treating older patients with a vitamin K antagonist may be warranted since thrombosis risk is more markedly increased than bleeding risk with rising age.
The study analyzed the hospital records of over 1500 patients.
The idea of low-dose tPA will likely not be abandoned despite recent findings.
Abnormal vital signs in these patients may be more common than previously thought.
The risk of stroke was reduced by as much as 80%.
Ticagrelor may have an opportunity to shine in patients already on aspirin or clopidogrel.
Low dose alteplase was not noninferior to standard dose for the primary outcome of death and disability at 90 days.
In the SOCRATES trial, patients were randomly assigned to ticagrelor or aspirin for 90 days.
The psychological consequences of stroke appear to influence outcomes.
Neurology Advisor Articles
- Migraine Relief After Chiropractic Manipulation Likely a Placebo Effect
- No Benefit for IV tPA Before Mechanical Thrombectomy in Ischemic Stroke
- Vitamin D Levels Linked to Migraine in Men
- Template Improves Quality of Report on MRI for Multiple Sclerosis
- Should EEG Periodic Discharges be Managed Similarly to Seizures?